Chris Hopkins, PhD, MBA , Chair

Chris Hopkins, PhD, MBA is biochemist/geneticist turned entrepreneur specializing in the creation of humanized animal models for rare disease biology discovery. Chris has a track record of translational success as an awardee of multiple Small Business Innovation Research. Chris is passionate in working with Rare Disease groups to help them progress their therapeutic programs quickly. He helped establish the CADASIL Disease Modeling Group (CDMG), developing models, finding biomarkers and testing therapeutic approaches to help treat and prevent the symptoms caused by dysfunction in the extracellular domain of NOTCH3. The CDMG brings together leading vascular biology researchers to: deploy omics technologies to help understand disease mechanisms and reveal biomarkers, obtain CADASIL-related grant funding, train and build a collaborative research community, and create model systems built so biomarker conservation can be assessed and high-throughput drug screens performed.

Thomas Caulfield, PhD

Thomas Caulfield, PhD, is the Founder and CEO of Digital Ether Computing, an innovative biotechnology firm specializing in AI-driven drug discovery and functional genomics, with a strategic focus on developing groundbreaking therapeutics for complex diseases, including neurodegeneration and cancer. He previously served as an Senior Associate Consultant and Associate Professor at Mayo Clinic, where he established a multidisciplinary research program combining computational chemistry, biochemistry, biophysics, and advanced in silico drug modeling and was Director for the Drug Discovery and Design Core Facility. Dr. Caulfield’s pioneering work integrates structural biology, generative AI, quantum-inspired simulations, and dynamic modeling to explore critical biological targets involved in neurological disorders and cancer at an atomic level. His research encompasses understanding intricate structure-function relationships governing protein dynamics, protein-protein interactions, and nucleic acid complexes, with an emphasis on translating these insights into therapeutic innovation. Leveraging sophisticated computational predictions coupled with rigorous biophysical validation methods, Dr. Caulfield’s teams have advanced numerous novel therapeutic agents, including small molecules, molecular glues, engineered proteins, exotic peptides, RNA therapeutics (aptamers and antisense oligonucleotides), and advanced nano-molecular interactors like PROTACs and Nexomorphs. His unique approach emphasizes entropy-driven learning algorithms, new AI frameworks, positioning his research at the forefront of precision medicine and computational innovation. Dr. Caulfield holds a PhD in Chemistry from Georgia Tech and has authored over 115 peer-reviewed scientific publications, as well as 65 patents. His distinguished career includes research leadership roles at institutions such as Mayo Clinic Ventures, reflecting his sustained commitment to advancing both fundamental science and translational therapeutic applications.

Clement Y. Chow, PhD

Clement Y. Chow, PhD is a professor in the Department of Human Genetics at the University of Utah School of Medicine. His lab is focused on developing precision medicine approaches for rare diseases by identifying modifier genes that can be targeted for therapeutic development, and performing drug repurposing screens for a number of different rare diseases. This employs quantitative and functional tools in a variety of model organisms to understand how genetic background can contribute to disease outcomes, and how we might take advantage of these differences to develop individualized therapies.

Sandra Talbird

Sandra Talbird, MSPH, served as a member of the cureCADASIL Board of Trustees for ten years, 2016-2025. She is currently Executive Director, Health Economics, at RTI International. There she designs and programs decision-analytic economic models, including cost-effectiveness, cost-utility, cost-benefit, and budget-impact models. She has also developed mathematical models including compartmental dynamic transmission models for infectious diseases and linear programs in various software packages. She has experience generating real-world evidence for economic models through retrospective analyses of patient registry data, medical chart review studies, and clinical trial data.

She has done research in infectious disease and vaccines, including treatment and prevention strategies for COVID-19, Ebola virus disease, HIV, acute and chronic hepatitis B, hepatitis C, seasonal influenza, invasive meningococcal disease, P. vivax and P. falciparum malaria, pertussis, pneumococcal disease, respiratory syncytial virus, tetanus, tuberculosis, and varicella zoster virus. Ms. Talbird is an active member of ISPOR. Her research has been presented at various professional conferences and published in several peer-reviewed journals, including AIDS, HIV Medicine, Pediatrics, Pharmacoeconomics, American Journal of Preventative Medicine, Value in Health, and Vaccine.

Fanny Elahi, MD, PhD

Fanny Elahi, MD, PhD is a physician-scientist and Assistant Professor in the Departments of Neurology, Neuroscience, and Pathology at the Icahn School of Medicine at Mount Sinai in New York City. Elahi’s work focuses on examining the link between disease of the brain’s small blood vessels and neurodegeneration. She is passionate about translating laboratory discoveries into clinical applications, and aims to inspire hope for a cure for CADASIL, Alzheimer’s Disease, Parkinson’s Disease, Frontotemporal Dementias, and other neurodegenerative disorders. In 2020, cureCADASIL and Elahi worked to form a collaborative group of investigators (the CADASIL Disease Modeling Group; CDMG) with the goal to share knowledge and resources to move forward drug discovery for CADASIL. For more information about Dr. Elahi, please visit https://vascbrain.com/.

Graeme Fielder, PhD

Graeme Fielder, PhD, is Chief Operating Officer at Avidobio (https://aviadobio.com/). He received his PhD degree in Molecular Medicine at the Liggins Institute, University of Auckland, Auckland, New Zealand, and Master of Business Administration (MBA) degree at Stanford University Graduate School of Business. After roles at pharmaceutical companies including Biomartin Pharmaceutical, Inc., San Rafael, CA, USA in 2014, and Astellas Gene Therapies, Inc. (Audentes Therapeutics, Inc.), San Francisco, CA, USA in 2017 -2020, he joined Avidobio as a founding team member in 2020. Avidobio’s current portfolio includes Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia (FTD) gene therapies focused on targeted and precise drug delivery and dosing for maximal biodistribution to the brain and spinal cord with a favorable safety profile.

Anne Joutel, MD, PhD

Anne Joutel, MD, PhD is a clinician-scientist trained in Neurology and Neurogenetics. She is currently a Research Director at the French National Institute of Health and Medical Research (Inserm) and leads a research group at the Institute of Psychiatry and Neurosciences of Paris (France). Her research focuses on understanding the mechanisms underlying cerebral small vessel disease (cSVD). Her laboratory leverages monogenic forms of cSVD, where a single gene defect leads to disease, as models to uncover the pathobiology of these complex disorders. Dr. Joutel has a longstanding research focus on CADASIL, the most common monogenic form of cerebral small vessel disease (cSVD). Her laboratory has made seminal contributions to its understanding, including the identification of NOTCH3 as the causative gene, the development of innovative mouse models, and the elucidation of NOTCH3‘s role in vascular physiology and disease mechanisms. She uncovered the critical impact of NOTCH3 accumulation and perturbations of the microvascular extracellular matrix (“matrisome”) in CADASIL pathogenesis, and demonstrated the preclinical efficacy of passive immunization targeting NOTCH3. In recognition of her groundbreaking work, she was awarded the Brain Prize by the Lundbeck Foundation in 2019.

Michelle A. McGuinness, MS, RAC

Michelle Mc Guinness is a biopharmaceutical leader with expertise in the quality, regulatory and compliance aspects of pharmaceutical manufacturing & marketing. She is a member of the Regulatory Affairs Professional Society and the American Society for Quality. Michelle understands the scientific aspects of CADASIL, as well as the impact that a rare disease has on a family. Ms. Mc Guinness’s father had CADASIL, and she is committed to advocacy, awareness & finding a cure for CADASIL.

Hugues Chabriat, MD, PhD

Hugues Chabriat is a tenured professor of neurology at Université Paris VII – Denis Diderot and the head of Dept. of Neurology at AP-HP – Hôpital Lariboisière (Paris, France). He has long been studying small vessel disease of the brain, in particular CADASIL. He has also a strong expertise in neuroimaging and particular interest in exploring the relationship between brain lesions and the occurrence of cognitive deficits and disability in small vessel disease.

Dr. Chabriat is a renowned expert in CADASIL and SVD. He is mainly involved in clinical and imaging research, particularly with respect to the relationships between cerebral lesions and the broad spectrum of clinical manifestations of SVD. He has pioneered the use of diffusion tensor imaging for assessing cerebral lesions in CADASIL and SVD. He has recently investigated other original aspects of SVD Chabriat and Dichgans have assembled and conducted a refined phenotypic analysis of the largest cohort of CADASIL patients . Dr. Chabriat will develop functional MRI in CADASIL patients and assemble a cohort of SVD patients.